S&P 500 index data: S&P 500 Copyright ©
All data supplied by Morningstar Real-Time Data. U.S. intraday real-time exchange quotes are sourced from BATS when available. End-of-day quotes for Nasdaq, NYSE, and Amex securities will appear 15 minutes after close. Graph times are Eastern Standard. © Copyright Morningstar, Inc .
|Lipocine Announces Completion of Enrollment in its SOAR Phase 3 Study for Oral Testosterone Replacement Therapy|
|Ventrus Biosciences Receives Date for Type B Pre-NDA Meeting With FDA for DOLIZEM (Diltiazem Hydrochloride Cream) in Anal Fissures|
|The Medicines Company Receives Complete Response Letter From FDA Requesting Additional Information for New Drug Application for Its Antiplatelet Agent Cangrelor|
|Second Product in Vernalis' Cough Cold Pipeline Achieves Proof-of-Concept|
|Discovery Labs Recruits Top Talent to Strengthen Scientific Leadership Team|
|SHAREHOLDER ALERT: Brower Piven Encourages Investors Who Have Losses in Excess of $100,000 From Investment in Sarepta Therapeutics, Inc. to Contact Brower Piven Before the March 28, 2014 Lead Plaintiff Deadline (SRPT)|
|Relypsa Announces Topline Results From Patiromer Phase 1 Onset-of-Action Study|
|TESARO Announces Successful Achievement of Primary and All Secondary Endpoints in Third and Final Phase 3 Trial of Rolapitant|
|Flamel Technologies Announces Receipt of Complete Response Letter From FDA Citing Issues at the Facility of the Supplier of the Active Ingredient|
|Relypsa Announces Commercial Manufacturing Agreement With DSM Fine Chemicals|
Click above to view more mutual fund data and stats for nda - Aurubis AG.